840 related articles for article (PubMed ID: 19505204)
1. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain.
Boulanger L; Zhao Y; Foster TS; Fraser K; Bledsoe SL; Russell MW
Curr Med Res Opin; 2009 Jul; 25(7):1763-73. PubMed ID: 19505204
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain.
Wu N; Chen S; Boulanger L; Fraser K; Bledsoe SL; Zhao Y
J Med Econ; 2009 Sep; 12(3):192-202. PubMed ID: 19705975
[TBL] [Abstract][Full Text] [Related]
3. Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin.
Zhao Y; Sun P; Watson P
Curr Med Res Opin; 2011 Apr; 27(4):785-92. PubMed ID: 21303196
[TBL] [Abstract][Full Text] [Related]
4. The medical costs of migraine and comorbid anxiety and depression.
Pesa J; Lage MJ
Headache; 2004 Jun; 44(6):562-70. PubMed ID: 15186300
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study on the impact of comorbid depression or anxiety on healthcare resource use and costs among diabetic neuropathy patients.
Boulanger L; Zhao Y; Bao Y; Russell MW
BMC Health Serv Res; 2009 Jun; 9():111. PubMed ID: 19566952
[TBL] [Abstract][Full Text] [Related]
6. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA.
Joyce AT; Smith P; Khandker R; Melin JM; Singh A
J Rheumatol; 2009 Apr; 36(4):743-52. PubMed ID: 19228658
[TBL] [Abstract][Full Text] [Related]
7. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
8. Labor market, financial, insurance and disability outcomes among near elderly Americans with depression and pain.
Tian H; Robinson RL; Sturm R
J Ment Health Policy Econ; 2005 Dec; 8(4):219-28. PubMed ID: 16385147
[TBL] [Abstract][Full Text] [Related]
9. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
10. Comorbidities, healthcare service utilization and costs for patients identified with painful DPN in a managed-care setting.
Ritzwoller DP; Ellis JL; Korner EJ; Hartsfield CL; Sadosky A
Curr Med Res Opin; 2009 Jun; 25(6):1319-28. PubMed ID: 19419344
[TBL] [Abstract][Full Text] [Related]
11. Insomnia-related comorbidities and economic costs among a commercially insured population in the United States.
Pollack M; Seal B; Joish VN; Cziraky MJ
Curr Med Res Opin; 2009 Aug; 25(8):1901-11. PubMed ID: 19530979
[TBL] [Abstract][Full Text] [Related]
12. The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorder.
Zhu B; Zhao Z; Ye W; Marciniak MD; Swindle R
J Nerv Ment Dis; 2009 Feb; 197(2):136-9. PubMed ID: 19214050
[TBL] [Abstract][Full Text] [Related]
13. Changes in opioid use and healthcare costs among U.S. patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapies.
Zhao Y; Wu N; Chen S; Boulanger L; Police RL; Fraser K
Curr Med Res Opin; 2010 Sep; 26(9):2147-56. PubMed ID: 20662557
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review.
Barrett AM; Lucero MA; Le T; Robinson RL; Dworkin RH; Chappell AS
Pain Med; 2007 Sep; 8 Suppl 2():S50-62. PubMed ID: 17714116
[TBL] [Abstract][Full Text] [Related]
15. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US.
Crown WH; Bresnahan BW; Orsini LS; Kennedy S; Leonardi C
Curr Med Res Opin; 2004 Dec; 20(12):1929-36. PubMed ID: 15701211
[TBL] [Abstract][Full Text] [Related]
16. Healthcare charges and utilization associated with diabetic neuropathy: impact of Type 1 diabetes and presence of other diabetes-related complications and comorbidities.
Zhao Y; Ye W; Boye KS; Holcombe JH; Swindle R
Diabet Med; 2009 Jan; 26(1):61-9. PubMed ID: 19125762
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of other diabetes-associated complications and comorbidities and its impact on health care charges among patients with diabetic neuropathy.
Zhao Y; Ye W; Boye KS; Holcombe JH; Hall JA; Swindle R
J Diabetes Complications; 2010; 24(1):9-19. PubMed ID: 18930413
[TBL] [Abstract][Full Text] [Related]
18. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
19. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
20. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder.
Asche CV; Joish VN; Camacho F; Drake CL
Curr Med Res Opin; 2010 Aug; 26(8):1843-53. PubMed ID: 20515321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
